

# Johan F Paulsson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/766546/publications.pdf>

Version: 2024-02-01

23  
papers

1,331  
citations

623734

14  
h-index

642732

23  
g-index

25  
all docs

25  
docs citations

25  
times ranked

2408  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice. <i>Cell</i> , 2009, 139, 1157-1169.	28.9	450
2	In Vivo Seeding and Cross-Seeding of Localized Amyloidosis. <i>American Journal of Pathology</i> , 2015, 185, 834-846.	3.8	235
3	Aberrant Processing of Human Proislet Amyloid Polypeptide Results in Increased Amyloid Formation. <i>Diabetes</i> , 2005, 54, 2117-2125.	0.6	109
4	Lovastatin ameliorates $\beta$ -synuclein accumulation and oxidation in transgenic mouse models of $\beta$ -synucleinopathies. <i>Experimental Neurology</i> , 2010, 221, 267-274.	4.1	106
5	Intracellular amyloid-like deposits contain unprocessed pro-islet amyloid polypeptide (proIAPP) in beta cells of transgenic mice overexpressing the gene for human IAPP and transplanted human islets. <i>Diabetologia</i> , 2006, 49, 1237-1246.	6.3	105
6	Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18563-18568.	7.1	76
7	Amyloid Deposition in Transplanted Human Pancreatic Islets: A Conceivable Cause of Their Long-Term Failure. <i>Experimental Diabetes Research</i> , 2008, 2008, 1-8.	3.8	33
8	Elucidation of the Binding Mode of the Carboxyterminal Region of Peptide YY to the Human Y <sub>2</sub> Receptor. <i>Molecular Pharmacology</i> , 2018, 93, 323-334.	2.3	28
9	Design of Y <sub>2</sub> Receptor Selective and Proteolytically Stable PYY <sub>3-36</sub> Analogues. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10519-10530.	6.4	27
10	High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus. <i>PLoS ONE</i> , 2014, 9, e93053.	2.5	23
11	Cellular clearance of circulating transthyretin decreases cell-nonautonomous proteotoxicity in <i>Caenorhabditis elegans</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E7710-E7719.	7.1	23
12	Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. <i>Diabetologia</i> , 2006, 50, 195-201.	6.3	20
13	The Design of a GLP-1/PYY Dual Acting Agonist. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 8268-8275.	13.8	17
14	Real-Time Monitoring of Apoptosis by Caspase-3-Like Protease Induced FRET Reduction Triggered by Amyloid Aggregation. <i>Experimental Diabetes Research</i> , 2008, 2008, 1-12.	3.8	16
15	The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs. <i>Scientific Reports</i> , 2021, 11, 21179.	3.3	13
16	Ferret islet amyloid polypeptide (IAPP): characterization of <i>in vitro</i> and <i>in vivo</i> amyloidogenicity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 222-228.	3.0	9
17	Extraneural manifestations of prion infection in GPI-anchorless transgenic mice. <i>Virology</i> , 2011, 411, 1-8.	2.4	8
18	Improving membrane binding as a design strategy for amphipathic peptide hormones: $\alpha$ -helix variants of PYY <sub>3-36</sub> . <i>Journal of Peptide Science</i> , 2012, 18, 579-587.	1.4	7

#	ARTICLE	IF	CITATIONS
19	A Parallel Semisynthetic Approach for Structure-Activity Relationship Studies of Peptide YY. ChemMedChem, 2013, 8, 1505-1513.	3.2	7
20	Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications. ACS Medicinal Chemistry Letters, 2013, 4, 1228-1232.	2.8	6
21	Rational Development of Stable PYY3-36 Peptide Y2 Receptor Agonists. Pharmaceutical Research, 2021, 38, 1369-1385.	3.5	5
22	Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. Acta Diabetologica, 2009, 46, 35-42.	2.5	4
23	The Design of a GLP-1/PYY Dual Acting Agonist. Angewandte Chemie, 2021, 133, 8349-8356.	2.0	1